Canada - English - Health Canada

naos - octinoxate; homosalate; avobenzone - lotion - 7.5%; 3%; 2.5% - octinoxate 7.5%; homosalate 3%; avobenzone 2.5% - sunscreen agents

United States - English - NLM (National Library of Medicine)

produits de soins pour la peau au lait de chevre canus inc - zinc oxide 25% w/w, kaolin 14.5% w/w - skin protectant helps treat and prevent diaper rash. stop use and ask and doctor if condition worsens or does not improve within 7 days or clear up and occur again within a few days

Canada - English - Health Canada

groupe marcelle inc - octinoxate; octocrylene; octisalate; avobenzone - cream - 7.5%; 5%; 5%; 3% - octinoxate 7.5%; octocrylene 5%; octisalate 5%; avobenzone 3% - sunscreen agents

Canada - English - Health Canada

dermtek pharma inc - octocrylene; octinoxate; octisalate; avobenzone - cream - 10%; 7.5%; 5%; 2% - octocrylene 10%; octinoxate 7.5%; octisalate 5%; avobenzone 2% - sunscreen agents

Canada - English - Health Canada

codif international - octisalate; titanium dioxide; octinoxate - cream - 2%; 5.35%; 6% - octisalate 2%; titanium dioxide 5.35%; octinoxate 6% - sunscreen agents

Canada - English - Health Canada

naos canada inc. - avobenzone; homosalate; octisalate - cream - 2.7%; 9%; 4.5% - avobenzone 2.7%; homosalate 9%; octisalate 4.5%

Canada - English - Health Canada

naos canada inc. - avobenzone; homosalate; octisalate - cream - 2.7%; 9%; 4.5% - avobenzone 2.7%; homosalate 9%; octisalate 4.5%

Canada - English - Health Canada

naos canada inc. - avobenzone; homosalate; octisalate - cream - 2.7%; 9%; 4.5% - avobenzone 2.7%; homosalate 9%; octisalate 4.5%

Canada - English - Health Canada

shiseido americas corporation dist - octinoxate; octocrylene; avobenzone - stick - 4.9%; 3%; 2.5% - octinoxate 4.9%; octocrylene 3%; avobenzone 2.5%

New Zealand - English - Medsafe (Medicines Safety Authority)

bayer new zealand limited - meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) - solution for injection - 469 mg/ml - active: meglumine gadopentetate 469 mg/ml (formed from gadolinium oxide, diethylenetriamine pentetic acid & meglumine) excipient: meglumine pentetic acid water for injection - for diagnostic use by intravenous administration only. cranial and spinal magnetic resonance imaging (mri) in particular for the demonstration of tumours and for further differential-diagnostic clarification in suspected meningioma, (acoustic) neurinoma, invasive tumours (e.g. glioma) and metastases; for the demonstration of small and/or isointense tumours; in suspected recurrence after surgery or radiotherapy; for the differentiated demonstration of rare neoplasms such as haemangioblastomas, ependymomas and small pituitary adenomas; for improved determination of the spread of tumours not of cerebral origin. additionally in spinal mri: differentiation of intra- and extramedullary tumours; demonstration of solid tumour areas in known syrinx; determination of intramedullary tumour spread. whole body mri including the facial skull, the neck region, the thoracic and abdominal space, the female breast, the pelvis and the active and passive locomotive apparatus and imaging of vessels throughout the body. in particular, magnevist permits diagnostic information: · for the demonstration or exclusion of tumours, inflammation and vascular lesions; · for determination of the spread and demarcation of these lesions; · for the differentiation of the internal structure of lesions; · for assessment of the circulatory situation of normal and pathologically changed tissues; · for the differentiation of tumour and scar tissue after therapy; · for the recognition of recurrent prolapse of a disk after surgery. · for the semi-quantitative evaluation of the renal function combined with anatomical organ diagnosis.